Agios Pharmaceuticals (NASDAQ:AGIO) Trading 8.5% Higher

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report)'s stock price was up 8.5% on Tuesday . The company traded as high as $32.84 and last traded at $32.78. Approximately 654,610 shares traded hands during trading, a decline of 19% from the average daily volume of 803,593 shares. The stock had previously closed at $30.21.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on AGIO shares. Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Tuesday, April 9th. JPMorgan Chase & Co. decreased their target price on shares of Agios Pharmaceuticals from $31.00 to $30.00 and set a "neutral" rating for the company in a research report on Friday, February 23rd. Finally, Royal Bank of Canada decreased their target price on shares of Agios Pharmaceuticals from $43.00 to $42.00 and set an "outperform" rating for the company in a research report on Friday, February 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $33.50.

Agios Pharmaceuticals Trading Up 5.3 %

The company has a market cap of $1.79 billion, a price-to-earnings ratio of -5.02 and a beta of 0.83. The firm's 50-day moving average price is $29.80 and its 200 day moving average price is $25.13.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.72) EPS for the quarter, missing the consensus estimate of ($1.64) by ($0.08). The company had revenue of $7.10 million for the quarter, compared to analyst estimates of $7.80 million. Agios Pharmaceuticals had a negative return on equity of 38.08% and a negative net margin of 1,312.64%. The business's quarterly revenue was up 65.1% compared to the same quarter last year. During the same period last year, the business earned $0.67 EPS. Analysts forecast that Agios Pharmaceuticals, Inc. will post -5.11 earnings per share for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In related news, insider James William Burns sold 1,708 shares of the stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $21.64, for a total value of $36,961.12. Following the transaction, the insider now directly owns 30,378 shares in the company, valued at approximately $657,379.92. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider James William Burns sold 1,708 shares of the stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $21.64, for a total value of $36,961.12. Following the transaction, the insider now directly owns 30,378 shares in the company, valued at approximately $657,379.92. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Cecilia Jones sold 1,886 shares of the stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $21.64, for a total value of $40,813.04. Following the completion of the transaction, the chief financial officer now owns 13,069 shares in the company, valued at $282,813.16. The disclosure for this sale can be found here. Insiders sold a total of 37,986 shares of company stock valued at $950,297 in the last quarter. 4.24% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. lifted its stake in Agios Pharmaceuticals by 96.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,429 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 700 shares in the last quarter. Quest Partners LLC bought a new position in Agios Pharmaceuticals during the 4th quarter valued at $41,000. Headlands Technologies LLC lifted its stake in Agios Pharmaceuticals by 31.3% during the 3rd quarter. Headlands Technologies LLC now owns 9,037 shares of the biopharmaceutical company's stock valued at $224,000 after acquiring an additional 2,153 shares in the last quarter. NEOS Investment Management LLC bought a new position in Agios Pharmaceuticals during the 4th quarter valued at $210,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Agios Pharmaceuticals by 25.7% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,502 shares of the biopharmaceutical company's stock valued at $260,000 after acquiring an additional 2,148 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.